Table 1.
Baseline demographic, clinical, laboratory and biological data of the entire cohort and the training and test cohorts for involved vs. uninvolved bone marrow.
| Characteritsic | Entire Population (97 Patients) |
Training Cohort (68 Patients) |
Test Cohort (29 Patients) |
|---|---|---|---|
| Age | 63.5 ± 12.5 | 64.3 ± 12.8 | 61.6 ± 11.8 |
| Female | 31/97 (32.0%) | 20/68 (29.4%) | 11/29 (37.9%) |
| Ann Arbor Stage | |||
| I–II | 14/97 (14.4%) | 12/68 (17.6%) | 2/29 (6.9%) |
| II–IV | 83/97 (85.6%) | 56/68 (82.4%) | 27/29 (93.1%) |
| Blastoid differentiation | 21/97 (21.6%) | 15/68 (22.1%) | 6/29 (20.7%) |
| Blastic | 18/97 (18.6%) | 12/68 (17.6%) | 6/29 (20.7%) |
| Pleomorphic | 3/97 (3.1%) | 3/68 (4.4%) | 0/29 (0%) |
| WBC (×109/L) | 10.5 ± 11.9 | 10.2 ± 12.4 | 10.7 ± 11.0 |
| LDH (U/L) | 232.3 ± 86.0 | 236.4 ± 97.2 | 222.4 ± 51.4 |
| ECOG ≥ 2 | 9/97 (9.3%) | 6/68 (8.8%) | 3/29 (10.3%) |
| Bone marrow involvement | 67/97 (69.1%) | 47/67 (70.1%) | 20/29 (70.0%) |
| REL | 33.0 ± 29.1% | 33.0 ± 29.6% | 32.9 ± 28.6% |
| ABS | 22.6 ± 23.6% | 24.5 ± 22.6% | 21.8 ± 22.0% |
| Ki-67 | 28.9 ± 23.7% | 29.3 ± 24.6% | 28.0 ± 22.0% |
WBC, white blood count; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group Performance Status; REL, percentage of involvement of cellular bone marrow; ABS, percentage of involvement relative to the entire marrow space.